Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Bile DNA sequencing helps identify hidden pancreatobiliary tumors (opens in a new tab)

news-medical.net · 2026-09-29

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Four of eight claims match the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

  • 4 supported
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredThe study included 95 patients undergoing their first ERCP for a biliary stricture radiologically suspicious for malignancy, with final malignant cases comprising 40 cholangiocarcinomas and 31 pancreatic ductal adenocarcinomas.View evidenceHide evidence

As stated95 patients; 40 cholangiocarcinomas; 31 pancreatic ductal adenocarcinomas

Why this verdict

The abstract profile supports 95 patients with biliary strictures under radiological suspicion of malignancy sampled at first ERCP. However, the stated final malignant composition of 40 cholangiocarcinomas and 31 pancreatic ductal adenocarcinomas is not reported in the supplied abstract-depth profile.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
Claim 2 of 8Not coveredAmong initially indeterminate strictures later confirmed as malignant, bile ULP-WGS had 51% sensitivity, and among ultimately benign cases it was negative in 23 of 24 cases, corresponding to 96% specificity.View evidenceHide evidence

As stated51% sensitivity; 96% specificity

Why this verdict

The 51% sensitivity among initially indeterminate patients later confirmed malignant and the 96% specificity for final benign strictures are supported. The exact benign denominator and numerator, 'negative in 23 of 24 cases,' are not provided in the abstract profile, which explicitly notes that the final benign case count and detailed contingency table are not reported.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
Claim 3 of 8Not coveredA supervised 50-region CNA classifier distinguished cholangiocarcinoma from pancreatic ductal adenocarcinoma with about 86% accuracy in the reference cohort and 85% in validation.View evidenceHide evidence

As stated86.4% and 85.0% accuracy

Why this verdict

The abstract profile supports a 50-region CNA classifier distinguishing CCA from PDAC with accuracy 0.864. It does not report a reference-cohort versus validation-cohort split or an 85.0% validation accuracy, and it notes that validation methodology is not detailed at abstract depth.

1

Study evidence

A supervised classifier based on a 50-region CNA feature set applied to bile cfDNA ULP-WGS data discriminated CCA from PDAC with reported accuracy 0.864.accuracy 0.864

“A supervised classifier based on discriminant analysis of principal components was used to distinguish CCA from PDAC.”
Claim 4 of 8Not coveredPatients who were both tumour-fraction positive and had mutations in at least three genes had worse overall survival than the remaining patients, with the combined genomic profile remaining independently associated with poorer survival after adjustment.View evidenceHide evidence

As statedmedian overall survival 5.1 months vs 13.7 months; adjusted hazard ratio 2.51

Why this verdict

The abstract profile supports the general finding that the combination of tumour fraction and tumour mutational burden identified a subgroup with poorer prognosis, while TF or TMB alone did not. It does not provide the threshold of mutations in at least three genes, median survival values, an adjusted hazard ratio, or evidence of independent association after adjustment.

1

Study evidence

Tumour fraction (TF) alone was not associated with overall survival.

“Tumour mutational burden (TMB) was assessed with the Bilemut panel.”
Claim 5 of 8SupportedA study published in eGastroenterology suggests that bile collected during routine ERCP could provide an additional source of tumour-derived genomic information.View evidenceHide evidence

Why this verdict

The abstract-profile evidence supports bile cfDNA ULP-WGS from samples collected at first ERCP as a complementary genomic source for tumour detection in biliary strictures. The story frames this cautiously as suggesting an additional source of tumour-derived genomic information.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
Claim 6 of 8SupportedRojo and colleagues evaluated ultra-low-pass whole-genome sequencing of bile cell-free DNA as a potentially scalable and cost-efficient approach for malignancy detection, tumour-origin classification and prognostic stratification.View evidenceHide evidence

Why this verdict

The paper profile states that the study evaluated bile cfDNA ULP-WGS as a potentially cost-effective/scalable approach for early malignancy detection, tumour-origin classification, and prognostic stratification. The hedged wording is consistent with the exploratory abstract-level conclusions.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
2

Study evidence

A supervised classifier based on a 50-region CNA feature set applied to bile cfDNA ULP-WGS data discriminated CCA from PDAC with reported accuracy 0.864.accuracy 0.864

“A supervised classifier based on discriminant analysis of principal components was used to distinguish CCA from PDAC.”
Claim 7 of 8SupportedIn ULP-WGS-positive patients whose malignancy was not established at the first ERCP, tumour DNA was detected a median of 38 days before conventional diagnosis, and in some cases more than 100 days earlier.View evidenceHide evidence

As statedmedian 38 days earlier; up to 499 days earlier

Why this verdict

The abstract profile states that, among initially indeterminate patients later confirmed malignant, tumour DNA was detected in 51% and anticipated final diagnosis by a median of 38 days, with seven patients detectable more than 100 days before routine diagnosis. The exact maximum lead time of 499 days in the presentation metadata is not verifiable from the abstract profile, but the claim text itself is supported.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
Claim 8 of 8SupportedThe article says the approach is not sensitive enough to exclude malignancy when negative and should not replace histopathology, but may help prompt faster repeat sampling or closer surveillance after an inconclusive ERCP.View evidenceHide evidence

Why this verdict

The paper profile frames bile ULP-WGS as complementary and exploratory, and the 51% sensitivity among initially indeterminate malignant cases supports the caution that a negative result should not rule out malignancy or replace histopathology. The suggested use after inconclusive ERCP is hedged and consistent with the reported early-detection lead-time rationale.

1

Study evidence

In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%

“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Initial first-ERCP classification was malignant n=26 or indeterminate n=69; this framing underlies the diagnostic-performance results.

    The story reports the overall cohort and later disease composition, but does not reflect the abstract’s initial malignant versus indeterminate classification counts.

    From Prospective clinical observational diagnostic evaluation

  • Matched bile versus plasma comparison: bile LP-/ULP-WGS showed higher sensitivity than plasma for tumour detection in matched samples.

    The story does not mention the matched plasma comparison, although it is included as part of the primary diagnostic contribution in the paper profile.

    From Prospective clinical observational diagnostic evaluation

  • Descriptive CNA profiling found recurrent chromosomal alterations in bile cfDNA that were consistent with tissue-based data.

    The story discusses tumour-derived genomic information and the classifier, but does not specifically cover the descriptive recurrent-CNA/tissue-consistency finding.

    From Descriptive CNA profiling (ULP-WGS, ichorCNA)

6 things the story did carry across
  • Primary diagnostic evaluation: bile cfDNA ULP-WGS at first ERCP in 95 patients with radiologically suspicious biliary strictures for early malignancy detection.
  • Detection in initially indeterminate but later malignant strictures: 51% detection and median 38-day lead time, with some detections more than 100 days before routine diagnosis.
  • Specificity for strictures with a final benign outcome was 96%, but abstract-level details lack the full contingency table and confidence intervals.
  • Tumour-origin classification: ULP-WGS-derived CNA patterns and a supervised 50-region classifier distinguished CCA from PDAC with reported accuracy 0.864.
  • Prognostic stratification: TF and TMB alone were not associated with overall survival, but their combination identified a poorer-prognosis subgroup.
  • Exploratory nature and validation limitations: the abstract profile lacks detailed thresholds, contingency tables, confidence intervals, validation strategy, and survival effect estimates; larger validation is needed.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate bile cfDNA ultra-low-pass whole-genome sequencing (ULP-WGS) at the first ERCP for early detection of malignancy in patients with biliary strictures (including comparison to plasma in matched samples).Prospective clinical observational diagnostic evaluationExpand

In plain English

Prospective clinical observational diagnostic evaluation of ultra-low-pass whole-genome sequencing (ULP-WGS) on bile cell-free DNA (cfDNA) collected at the first ERCP from 95 patients with biliary strictures. Tumour fraction (TF) and copy-number alterations (CNAs) were inferred with ichorCNA; tumour mutational burden (TMB) assessed with a targeted Bilemut panel. In matched samples bile ULP-/LP-WGS had higher sensitivity than plasma. Among patients initially classified malignant at first ERCP, ctDNA was detected in 73%; among those initially indeterminate but later confirmed malignant, ctDNA was detected in 51% and anticipated final diagnosis by a median of 38 days (with seven patients >100 days lead time). Specificity for strictures with a final benign outcome was 96%. CNA profiling yielded recurrent alterations consistent with tissue data and a 50-region CNA classifier discriminated cholangiocarcinoma (CCA) from pancreatic ductal adenocarcinoma (PDAC) with accuracy 0.864. TF or TMB alone were not associated with overall survival, but their combination identified a subgroup with poorer prognosis. The authors frame the study as exploratory and propose bile ULP-WGS at first ERCP as a complementary, scalable strategy for early malignancy detection, tumour-origin classification, and prognostic stratification.

Key findings

  • In patients initially classified malignant at first ERCP, bile ULP-WGS detected circulating tumour DNA (ctDNA) in 73% of cases.73%
  • Among patients initially classified as indeterminate but later confirmed malignant, tumour DNA was detected in 51%, anticipating final diagnosis by a median of 38 days; in seven patients ctDNA was detectable >100 days before routine diagnosis.51%; median lead-time 38 days; 7 patients >100 days
“Bile samples from 95 patients with biliary strictures under radiological suspicion of malignancy, classified as malignant (n=26) or indeterminate (n=69) based on the result of cytology or biopsy at the first endoscopic retrograde cholangiopancreatography (ERCP), were analysed by ULP-WGS.”
What this piece can’t prove
  • Abstract does not report sequencing depth, ichorCNA thresholds, or detailed diagnostic contingency tables and confidence intervals.
  • Subgroup sample sizes are limited (e.g., initially malignant n=26), which may affect precision of subgroup performance estimates reported in abstract.

2 further details could not be confirmed from the summary.

2human in vivoUse bile ULP-WGS-derived copy-number alteration (CNA) patterns to discriminate tumour origin (cholangiocarcinoma (CCA) vs pancreatic ductal adenocarcinoma (PDAC)) via a supervised classifier.supervised classification (discriminant analysis of principal components)Expand

In plain English

The study applied ultra-low-pass WGS of bile cfDNA to derive copy-number alteration (CNA) profiles and developed a supervised classifier (discriminant analysis of principal components) using a 50-region CNA feature set to discriminate tumour origin (CCA vs PDAC). The classifier is reported to achieve an accuracy of 0.864.

Key findings

  • A supervised classifier based on a 50-region CNA feature set applied to bile cfDNA ULP-WGS data discriminated CCA from PDAC with reported accuracy 0.864.accuracy 0.864
“A supervised classifier based on discriminant analysis of principal components was used to distinguish CCA from PDAC.”
What this piece can’t prove
  • Class-specific sample sizes for CCA versus PDAC are not provided, preventing assessment of class balance and robustness.
  • Only overall accuracy is reported; sensitivity, specificity, predictive values, AUC, and uncertainty estimates (e.g., confidence intervals) are not provided.
  • No information on independent external validation or prospective evaluation to confirm generalisability.

2 further details could not be confirmed from the summary.

3human in vivoAssess prognostic stratification using bile ULP-WGS tumour fraction (TF) and targeted-panel tumour mutational burden (TMB), including their combination, against overall survival.Observational prognostic biomarker analysis (bile cfDNA TF and TMB vs overall survival)Expand

In plain English

Exploratory prognostic biomarker analysis assessing whether tumour fraction (TF) from bile ULP-WGS (ichorCNA) and tumour mutational burden (TMB) from a targeted Bilemut panel, individually or combined, are associated with overall survival (OS). Kaplan–Meier curves and log-rank tests were used; neither TF nor TMB alone was associated with OS, but the combination identified a subgroup with poorer prognosis.

Key findings

  • Tumour fraction (TF) alone was not associated with overall survival.
  • Tumour mutational burden (TMB) alone was not associated with overall survival.
“Tumour mutational burden (TMB) was assessed with the Bilemut panel.”
What this piece can’t prove
  • No information provided on follow-up duration, censoring patterns, or whether multivariable/time-dependent analyses were performed.
  • Exploratory finding requiring validation in larger, well-characterized cohorts with full methodological transparency.

2 further details could not be confirmed from the summary.

4human in vivoCharacterize recurrent CNAs in bile cfDNA and compare them to known tissue-based chromosomal alteration patterns.Descriptive CNA profiling (ULP-WGS, ichorCNA)Expand

In plain English

Descriptive CNA profiling of bile cell-free DNA (cfDNA) using ultra-low-pass whole-genome sequencing (ULP-WGS) and ichorCNA identified recurrent chromosomal copy-number alterations; the authors state these recurrent CNAs are consistent with previously reported tissue-based chromosomal alteration patterns.

Key findings

  • CNA profiling of bile cfDNA identified recurrent chromosomal copy-number alterations reported to be consistent with tissue-based chromosomal alteration patterns.
“CNA profiling revealed recurrent chromosomal alterations consistent with tissue-based data”
What this piece can’t prove
  • It is unclear whether recurrent CNAs were derived from the full cohort or a malignant/subset of samples.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 36 candidate papers

And 30 more candidates considered.